Seagen Inc. with ticker code (SGEN) now have 11 analysts in total covering the stock. The consensus rating is pointing to ‘hold’. The range between the high target price and low target price is between $229.00 and $228.00 and has a mean target at $228.91. Given that the stocks previous close was at $212.72 this would imply there is now a potential upside of 7.6%. There is a 50 day moving average of $214.02 and the 200 day MA is $200.57. The market cap for the company is 40.21B. The stock price is currently at: $213.13 USD
The potential market cap would be $43,270,089,354 based on the market consensus.
The company has a dividend yield of 5.95%. Other points of data to note are a P/E ratio of -, revenue per share of $12.29 and a -12.94% return on assets.
Seagen Inc. is a biotechnology company that develops and commercializes targeted therapies to treat cancer. The Company is engaged in commercializing ADCETRIS, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers; TUKYSA, or tucatinib, for the treatment of certain metastatic human epidermal growth factor receptor 2 (HER2) -positive breast and colorectal cancers, and TIVDAK, or tisotumab vedotin-tftv, for the treatment of certain metastatic cervical cancers. It is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients. Its programs including ADCETRIS, PADCEV and TIVDAK, are based on the Company’s antibody-drug conjugate (ADC) technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells.
